EICHOR
● Not Yet Recruiting
Oritavancin for CIED Infections With MDR Gram-positive Cocci
Condition: Cardiac Implantable Electronic Device Infections · Infective Endocarditis · Multidrug-resistant Bacteria Screening · Sponsor: Medical University of Silesia
About this study
The study aimed to conduct a randomized, non-inferiority controlled trial to compare the short- and medium-term efficacy and safety of two antibiotic dosage regimens in cardiac implantable electronic devices (CIED) infections with multidrug-resistant Gram-positive cocci: 1) single-dose therapy with a long-half-life antibiotic (oritavancin) vs. standard 7-14 days of therapy with a short-half-life antibiotic (vancomycin) for CIED surgical incision site or pocket infection; and 2) fractionated therapy with a long-half-life antibiotic (oritavancin) at seven-day intervals compared to standard therapy with a short-half-life antibiotic (vancomycin) fractionated in 2-3 daily doses in cases of lead-related infectious endocarditis.
This description comes directly from the study's public registry record.
Talk to the study team
Danuta Loboda, MD, PhD · (+48) 32 359-89-90 · dloboda@sum.edu.pl
Beata Sarecka-Hujar, Professor · bsarecka-hujar@sum.edu.pl
Always discuss trial participation with your own doctor first.
Locations (1)
| Department of Electrocardiology and Heart Failure, Medical University of Silesia in Katowice | Katowice, Silesian Voivodeship, Poland | — |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07013552